<DOC>
	<DOCNO>NCT00075374</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy , docetaxel , use different way stop tumor cell divide stop grow die . It yet know docetaxel regimen effective non-small cell lung cancer . PURPOSE : Randomized phase II trial compare effectiveness two regimen docetaxel treat patient previously receive chemotherapy unresectable stage IIIB stage IV non-small cell lung cancer .</brief_summary>
	<brief_title>Two Regimens Docetaxel Treating Patients Who Have Not Received Chemotherapy For Unresectable Stage IIIB Stage IV Non-Small Cell Lung Cancer</brief_title>
	<detailed_description>OBJECTIVES : Primary - Compare effect two different schedule docetaxel incidence grade 3 4 toxic effect older poor performance chemotherapy-na√Øve patient unresectable stage IIIB IV non-small cell lung cancer . Secondary - Compare overall survival patient treat regimen . - Compare response rate patient treat regimen . - Compare incidence serious adverse event patient treat regimen . - Determine quality life patient treat regimen . OUTLINE : This open-label , randomize , multicenter study . Patients randomize 1 2 treatment arm . - Arm I : Patients receive docetaxel IV 1 hour day 1 . Treatment repeat every 21 day absence disease progression unacceptable toxicity . - Arm II : Patients receive docetaxel IV 30 minute day 1 , 8 , 15 . Treatment repeat every 28 day absence disease progression unacceptable toxicity . Quality life assess baseline , every 2 course study treatment , study completion . Patients follow 1 month every 2-3 month thereafter . PROJECTED ACCRUAL : A total 210-230 patient ( 105-115 per treatment arm ) accrue study .</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically cytologically confirm nonsmall cell lung cancer Unresectable stage IIIB IV disease No untreated brain leptomeningeal metastasis Treated patient must neurologically stable adverse effect prior therapy must resolve grade 2 less completion treatment No symptomatic ( i.e. , require thoracentesis ) pleural effusion No clinically significant ( i.e. , grade 3 great ) pericardial effusion PATIENT CHARACTERISTICS : Age 18 Performance status ECOG 02 ( 70 year age ) OR ECOG 2 ( 70 year age ) Life expectancy Not specify Hematopoietic Absolute neutrophil count least 1,500/mm^3 Platelet count least 100,000/mm^3 Hemoglobin least 8.0 g/dL Hepatic Bilirubin normal AST ALT great 2.5 time upper limit normal ( ULN ) alkaline phosphatase great ULN OR Alkaline phosphatase great 4 time ULN ALT AST great ULN Renal Not specify Other Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception 6 month study participation No grade 2 great peripheral neuropathy No prior hypersensitivity reaction taxanes product contain polysorbate 80 No active malignancy except carcinoma situ cervix basal cell skin cancer No psychological , familial , sociological , geographical condition would preclude study treatment followup PRIOR CONCURRENT THERAPY : Biologic therapy Not specify Chemotherapy No prior chemotherapy Endocrine therapy Not specify Radiotherapy Recovered prior radiotherapy ( i.e. , side effect resolve grade 2 less ) No concurrent radiotherapy Surgery More 3 week since prior major surgery Other More 30 day since prior anticancer investigational drug Concurrent supportive care investigational agent allow</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2014</verification_date>
	<keyword>stage IIIB non-small cell lung cancer</keyword>
	<keyword>stage IV non-small cell lung cancer</keyword>
	<keyword>recurrent non-small cell lung cancer</keyword>
</DOC>